Calidi Biotherapeutics (CLDI)Director sold ~$1.2K

~$1.2K

Approx. value · 850 sh @ $1.46

77K

Holds after · shares reported

Traded

Dec 12, 2025

Filed

Dec 17, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 27, 2025Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and signed an important agreement (and 1 more item)“The information in Item 1.01 above is incorporated herein by reference.”
2. Nov 13, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Dec 12, 2025 · this disclosureInsiderDirector sold ~$1.2K of CLDI shares in the open market

What came next

1. Jan 28, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
2. Mar 5, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
3. Mar 27, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Mar 29, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On March 29, 2026, Mr. Allan J. Camaisa, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Nominating and Corporate Governance Committee of the Board that, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2026 annual stockholder meeting.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Calidi Biotherapeutics

OQRO holds no insider, Congress, fund or contract record for Calidi Biotherapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLDI page.

Other recent filings by Allan Camaisa, Director

• SEC Form 4 at Calidi Biotherapeutics (CLDI)Dec 19, 2024

The full history of Allan Camaisa, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Calidi Biotherapeutics

• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Dec 19, 2024

Everything OQRO holds on this company is on its CLDI page.